Aura Biosciences (AURA) Cash from Operations Growth (3y) (2023 - 2026)
Aura Biosciences (AURA) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 34.32% |
| 10 | Aura Biosciences | 485.29 Mn | 400.49 Mn | - | -22.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.12% |
| Dec 31, 2025 | -4.28% |
| Sep 30, 2025 | -23.25% |
| Jun 30, 2025 | -25.03% |
| Mar 31, 2025 | -15.39% |
| Dec 31, 2024 | -25.61% |
| Sep 30, 2024 | -20.68% |
| Jun 30, 2024 | -35.40% |
| Mar 31, 2024 | -68.22% |
| Dec 31, 2023 | -66.65% |